| HTRA2 — HtrA Serine Peptidase 2 | |
|---|---|
| Symbol | HTRA2 |
| Full Name | HtrA Serine Peptidase 2 |
| Chromosome | 2p13.1 |
| NCBI Gene | 27429 |
| Ensembl | ENSG00000103472 |
| OMIM | 606476 |
| UniProt | O43464 |
| Protein Name | HtrA2 / Omi |
| Protein Length | 458 amino acids |
| Molecular Weight | 48 kDa (precursor), 35 kDa (active protease) |
| Brain Expression | High: substantia nigra, striatum, cortex, hippocampus |
| Subcellular Localization | Mitochondrial intermembrane space |
| Associated Diseases | Parkinson's Disease, Huntington's Disease, Stroke |
Htra2 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
HTRA2 (HtrA Serine Peptidase 2, also known as Omi) is a nuclear-encoded mitochondrial serine protease that plays critical roles in cellular protein quality control and apoptosis regulation[1]. The protein is synthesized in the cytosol with an N-terminal mitochondrial targeting sequence and imported into the mitochondrial intermembrane space, where it functions as both a molecular chaperone and serine protease[2].
HTRA2 has attracted significant attention in neurodegenerative disease research due to its essential role in mitochondrial homeostasis and its involvement in Parkinson's disease (PD) pathogenesis[3]. Heterozygous missense mutations in HTRA2 have been associated with increased risk of sporadic PD, while homozygous mutations cause a rare form of neurodegeneration with tremor, ataxia, and dementia[4].
The HTRA2 gene is located on chromosome 2p13.1 and consists of 8 exons spanning approximately 3.5 kb[1:1]. The gene encodes a precursor protein of 458 amino acids that undergoes processing to generate the mature, active protease.
HTRA2 contains several functional domains[2:1]:
HTRA2 functions as a key component of the mitochondrial protein quality control system[2:2][5]:
Under cellular stress conditions, HTRA2 is released from mitochondria into the cytosol[6]:
Key substrates of HTRA2 include[6:1][7]:
HTRA2 is highly expressed in regions vulnerable to neurodegenerative processes[3:1]:
The high expression in substantia nigra explains the particular vulnerability of dopaminergic neurons in PD[3:2].
Within cells, HTRA2 localizes to:
HTRA2 mutations were first linked to PD in 2005 by Strauss et al.[3:3]:
Associated Mutations:
| Mutation | Effect | Frequency |
|---|---|---|
| G399S | Reduced protease activity | ~3% of sporadic PD |
| A141S | Impaired mitochondrial import | Rare |
| P143S | Decreased oligomerization | Rare |
Mechanism:
HTRA2 plays a protective role in Huntington's disease models[8]:
HTRA2 is involved in ischemic brain injury[9]:
HTRA2 maintains mitochondrial homeostasis through[2:3][5:1]:
Under various cellular stresses, HTRA2 function is modulated[6:2]:
HTRA2 interacts with several key proteins:
Pharmacological approaches to enhance HTRA2 function[10]:
Viral vector delivery of wild-type HTRA2:
HTRA2 has potential as a biomarker:
Htra2 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Htra2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Strauss KA, Jinks RN, Saran N, et al. HTRA2/OMI deficiency in mitochondria: evidence for a new mechanism of neurodegeneration. J Neurosci Res. 2020;98(12): 2492-2507. PubMed
Zhang Y, James M, Smith E, et al. Mitochondrial serine protease HTRA2 in Parkinson's disease and its therapeutic potential. Mol Neurobiol. 2019;56(8): 5625-5637. PubMed
Park S, Choi J, Kim H, et al. HTRA2 mutations in neurodegenerative disease: from mitochondria to apoptosis. Cell Death Discov. 2018;4: 32. PubMed
Whitworth AJ, Wes PD, Pallanck LJ. Mitochondrial dysfunction: an emerging link in neurodegeneration. EMBO Rep. 2008;9(2): 110-113. PubMed
Van Gool B, De Vocht N, Maes W, et al. HTRA2 deficiency causes vulnerability to age-related mitochondrial dysfunction. Neurobiol Aging. 2017;53: 140-148. PubMed
Liu W, Duan Q, Wang J, et al. HTRA2 regulates mitochondrial quality control in Parkinson's disease. Redox Biol. 2021;45: 102041. PubMed
Agostini M, Melino G. The emerging role of serine proteases in neuronal death and survival. Neurosignals. 2017;25(1): 1-10. PubMed
Bogaerts V, Nuytemans K, Reumers J, et al. Genetic variability in the mitochondrial serine protease HTRA2 contributes to Parkinson's disease risk. Mol Genet Metab. 2008;93(1): 33-40. PubMed
Zhang Y, et al. (2010). Structure and function of HTRA2. J Biol Chem, 285(45), 34557-34564. ↩︎ ↩︎ ↩︎ ↩︎
Strauss KM, et al. (2005). Loss-of-function mutations in HTRA2 cause neurodegeneration. Nat Genet, 37(12), 1317-1319. ↩︎ ↩︎ ↩︎ ↩︎
Bogaerts V, et al. (2008). HTRA2 mutations in European PD cohorts. Neurology, 71(22), 1790-1795. ↩︎ ↩︎
Vaux D, et al. (2011). Mitochondrial HTRA2 and protein quality control. Cell Death Differ, 18(6), 939-949. ↩︎ ↩︎
Zhang Y, et al. (2012). HTRA2 release and apoptosis. Mol Cell Biol, 32(15), 3024-3036. ↩︎ ↩︎ ↩︎
Li B, et al. (2014). HTRA2 and XIAP in cancer and neurodegeneration. Oncogene, 33(17), 2245-2255. ↩︎
Restelli LM, et al. (2015). HTRA2 in Huntington's disease models. Hum Mol Genet, 24(15), 4248-4262. ↩︎
Zheng Y, et al. (2016). HTRA2 in cerebral ischemia. J Cereb Blood Flow Metab, 36(12), 2062-2074. ↩︎
Liu YH, et al. (2020). HTRA2 modulators for neurodegeneration. Pharmacol Res, 158, 104865. ↩︎